YAZICI, A. Et Al. 2022. A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry. SCIENTIFIC REPORTS , vol.12, no.1 .

YAZICI, A., ÖZDEMİR IŞIK, Ö., Dalkilic, E., KOCA, S. S., PEHLİVAN, Y., Senel, S., ... Inanc, N.(2022). A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry. SCIENTIFIC REPORTS , vol.12, no.1.

YAZICI, AYTEN Et Al. "A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry," SCIENTIFIC REPORTS , vol.12, no.1, 2022

YAZICI, AYTEN Et Al. "A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry." SCIENTIFIC REPORTS , vol.12, no.1, 2022

YAZICI, A. Et Al. (2022) . "A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry." SCIENTIFIC REPORTS , vol.12, no.1.

@article{article, author={AYTEN YAZICI Et Al. }, title={A national, multicenter, secondary data use study evaluating efficacy and retention of first-line biologic treatment with tocilizumab in patients with rheumatoid arthritis in real-life setting: results from TURKBIO registry}, journal={SCIENTIFIC REPORTS}, year=2022}